71875-81-5

Basic information

• Product Name: Trans-4-(Maleimidomethyl)cyclohexanecarboxylic Acid-NHS
• Synonyms: Trans-4-(Maleimidomethyl)cyclohexanecarboxylic Acid-NHS;trans-2,5-Dioxopyrrolidin-1-yl 4-((2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)methyl)cyclohexanecarboxylate;trans-2,5-Dioxopyrrolidin-1-yl 4-((2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)
• CAS NO: 71875-81-5
• Molecular Formula: C₁₆H₁₈N₂O₆
• Molecular Weight: 334.32392
• Mol File: 71875-81-5.mol
• Article Data: 8

Chemical Properties

• Melting Point: 171-174 °C(Solv: acetone (67-64-1); methanol (67-56-1))
• Boiling Point: 501.7±42.0 °C(Predicted)
• Appearance: /
• Density: 1.42±0.1 g/cm3(Predicted)
• Storage Temp.: Inert atmosphere,Store in freezer, under -20°C
• PKA: -2.24±0.20(Predicted)
• CAS DataBase Reference: Trans-4-(Maleimidomethyl)cyclohexanecarboxylic Acid-NHS(CAS DataBase Reference)
• NIST Chemistry Reference: Trans-4-(Maleimidomethyl)cyclohexanecarboxylic Acid-NHS(71875-81-5)
• EPA Substance Registry System: Trans-4-(Maleimidomethyl)cyclohexanecarboxylic Acid-NHS(71875-81-5)

Safety Data

• Hazardous Substances Data: 71875-81-5(Hazardous Substances Data)

Usage

General Description

Trans-4-(Maleimidomethyl)cyclohexanecarboxylic Acid-NHS is a chemical compound that is commonly used in bioconjugation and crosslinking applications. It consists of a maleimide group, which is known for its reactivity towards thiol-containing molecules, and an NHS ester, which allows for the covalent attachment of the compound to primary amines. This reactivity makes it a valuable tool for the conjugation of proteins, peptides, and other biomolecules, as well as for the creation of targeted drug delivery systems and various biotechnology applications. Additionally, the cyclohexane ring in the molecule provides stability and rigidity, making it suitable for use in a wide range of experimental conditions. Overall, Trans-4-(Maleimidomethyl)cyclohexanecarboxylic Acid-NHS is a versatile and valuable reagent in the field of chemical biology and biochemistry.

Upstream product

• 108-31-6 maleic anhydride 
• 6066-82-6 1-hydroxy-pyrrolidine-2,5-dione 
• 1197-18-8 trans-4-aminomethyl-cyclohexyl-carboxylic acid 
• 1337538-63-2 trans-2,5-dioxo-1-pyrrolidinyl 4-{[[(2E)-4-[(2,5-dioxo-1-pyrrolidinyl)oxy]-1,4-dioxo-2-buten-1-yl]amino]methyl}tranexamate 
• 953817-12-4 C₁₂H₁₇NO₅ 
• 69907-68-2 trans-4-([(2Z)-3-carboxyprop-2-enoyl]aminolmethyl)cyclohexanecarboxylic acid 
• 69907-67-1 (1r,4r)-4-((2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)methyl)cyclohexane-1-carboxylic acid 
• 5672-89-9 N-trifluoroacetoxy succinimide 

Downstream Products

• 1292779-17-9 cyclo(L-Arginyl-glycyl-L-asparagyl-D-phenylalanyl-L-[εN-(trans-[4-(1-maleimido)methyl]cyclohexylcarbonyl)]lysine) trifluoroacetate 
• 1337538-59-6 C₂₂H₂₉N₃O₇ 
• 1337538-58-5 6-((1r,4r)-4-((2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)methyl)cyclohexanecarboxamido)hexanoic acid 

Relevant articles and documents

Refining method of SMCC

The invention relates to the purification/refining of a compound, and specifically discloses a refining method of SMCC. The refining method disclosed by the invention comprises the following steps: taking acetonitrile as the solvent of a SMCC crude produc

PHARMACEUTICAL COMPOSITIONS COMPRISING MACROLIDE DIASTEREOMERS, METHODS OF THEIR SYNTHESIS AND THERAPEUTIC USES

The disclosure relates to compositions comprising diastereomer of a macrolide exhibiting improved therapeutic profile in the context of inhibiting cell proliferation compared to the corresponding compositions comprising mixture of diastereomers. The discl

In situ formation of N-trifluoroacetoxy succinimide (TFA-NHS): One-pot formation of succinimidyl esters, N-trifluoroacetyl amino acid succinimidyl esters, and N-maleoyl amino acid succinimidyl esters

A method for the in situ formation of N-trifluoroacetoxy succinimide (TFA-NHS) and its application in the formation of succinimidyl esters is presented. The developed method provides N-trifluoroacetyl and N-maleoyl amino acid succinimidyl esters from a variety of amino acids using a one-pot, high-yielding protocol. Investigations into the formation of an N-maleoyl amino acid succinimidyl ester supported the proposal of a revised reaction mechanism, and contributed to the optimization of the reaction conditions.